This episode is Sponsored by Resoundant.
What can a NASH disease model teach us about treating patients with Advanced Fibrosis (F2/F3) in terms of the economic and medical rationales for therapy and optimal approaches?
This episode is Sponsored by Resoundant.
What unique challenges arise when building a disease model for NASH prevalence and what strategies do leading modelers use to overcome them?
This episode is Sponsored by Resoundant.
How can epidemiology-driven data modeling improve our setting strategies and targets for diagnostic and drug development?
This Episode is Sponsored by Madrigal Pharmaceuticals: CLDF opted for a Liver Connect program that featured conversations between sizable groups of experts instead of lengthy scientific presentations. How well did it work for panelists?
This Episode is Sponsored by Madrigal Pharmaceuticals: Once we acknowledge the potential for economic, social and medical damage that the increasing trend toward adolescent and pediatric NAFLD will cause, what solutions do we have? Can Liver Health education be effective?
This Episode is Sponsored by Madrigal Pharmaceuticals: What Can We Learn About Health Disparities In NASH Epidemiology and Treatment From the Content of NASH Connect?
This Episode is Sponsored by Madrigal Pharmaceuticals: What does CLDF President Zobair Younossi have to say about Liver Connect, NASH Connect, and the needs of the Fatty Liver community?
This Episode Is Sponsored By Madrigal Pharmaceuticals. What Insights About NASH and NAFLD Emerged From the Chronic Liver Disease Foundation’s 2nd Annual Liver Connect and NASH Connect?
Sponsored by Histoindex: How Can an Informed Application of Artificial Intelligence Improve Ballooned Hepatocyte Identification and Analysis in Advanced Fibrosis and Cirrhosis?
This Episode is Sponsored By HistoIndex: How can a reassessment of the way we analyze ballooned hepatocyte cells in clinical trials reshape drug development practices and the success rates in clinical trials?
This Episode is Sponsored by Histoindex: Do the Semi-Quantitative Rules We Apply to Ballooned Hepatocyte Analysis Inherently Create Error?
This Episode is Sponsored By Histoindex: What Can We Learn about the Sources of Statistical Error We Create in Ballooned Hepatocyte Analysis and How Can We Manage It Better?
This Episode is Sponsored By HistoIndex: Do inconsistent analyses of ballooned hepatocytes between different hepatopathologists lead to negative results in NASH Clinical Trials?
This Episode is Sponsored By Histoindex: How have complex ballooned hepatocytes have confounded NAS scores and clinical trials, and can AI serve as the foundation for a solution?
What is the impact of the NICE Draft Guidance on Community and Primary Care NAFLD Screening with FibroScan not analyzing the long-term impact of a decision not to compensate on health care in the UK?
Does the NICE Draft Guidance and methodology reveal a bad fit between the NICE mode of analysis and wellness-oriented solutions like early NAFLD screening?
What kinds of data and issues influence how NICE assesses a process like FibroScan Community and Primary Care NAFLD Screening?
What kinds of data provide the best, most accurate planning for assessing the health economics of Community and Primary Care liver screening with FibroScan?
What can we learn about prospects for community screening for NAFLD from the NICE draft guidance on this issue?
Throughout this podcast, panelists uncovered a large set of actions that might improve NASH care for those Black Americans who have the disease while suggesting a range of solutions, some more realistic or faster to achieve than others.
With so many major clinical trials for Fatty Liver drugs recruiting over the next couple of years, we have an opportunity to study effects on Black Americans from inception, instead of assuming these drugs work the same in different racial groups only to find, some years later, that we were wrong.
In non-Hispanic Black Americans, NASH Prevalence is lower but the progression from NASH cirrhosis to HCC is faster and liver transplants are harder to receive. Why is this so?
Although Non-Hispanic Black Americans have lower prevalence of NASH and NAFLD than other demographic groups, this disease can have significant negative effects on this sector if we do not focus better and do more, starting now.
Although non-Hispanic Black Americans experience lower rates of Fatty Liver Disease, Social Determinants of Health (SDOH) lead to less favorable outcomes when the disease occurs.
Work flows for NAIL-NIT: Retrospective analysis planning to produce results in 1-2 years, then prospective studies planning to produce results in 4-6 years.
How can data from NAIL-NIT address the challenges of the NAS score and provide more robust data to diagnose and treat individual patients with the optimal therapy?
How does NAIL-NIT looks to improve on the challenges of histopathology?
NAIL-NIT Study Co-Directors and Steering Committee members from pharmaceutical companies discuss their motivations and why they encourage others to join them
Introducing the NAIL-NIT Consortium: a multi-developer effort to link non-invasive testing (and specific tests) directly to outcomes for Fatty Liver patients
As NASH Prevalence grows, how many patients should we be screening for NAFLD and at what age should we start?
As NAFLD prevalence grows, what can we learn from US and UK data and clinical experience about the value of early NASH diagnosis and education for Fatty Liver patients?
What can the SUNN Study teach us about NASH and NAFLD prevalence in the US today as well as about patient education?
What Can This Recent Study Tell Us About NAFLD and NASH Prevalence in Germany and How To Monitor For It?
What are the implications of the large and growing estimates of NAFLD prevalence on the healthcare system’s ability to screen patients appropriately and route them on the proper treatment pathways?
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?
As efficacious NASH drugs near the market, what steps can we take to ensure that patients receive treatment early enough in the course of therapy?
How does the misalignment of liver patients’ needs and nursing availability limit chances to intervene early in the course of Fatty Liver disease?
Nursing KOLs discuss the extensive backgrounds and diverse skill sets they bring to the frustrating challenge of educating Fatty Liver patients early in disease progression.
An all-star panel of liver nurses and advanced nurse practitioners join Louise Campbell and Stephen Harrison to explore ways these experts can play a broader role in NASH education and patient management. Are We Taking Full Advantage of the Skills and Knowledge That Liver Nurses and Advanced Nurse Practitioners Bring To NASH Education and Patient Care?
Jeff Lazarus And Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to consider innovative elements for a program like this along with the outcomes they would like these programs to produce.
Jeff Lazarus And Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to discuss the structural healthcare issues that are shaping the Fatty Liver pandemic and why education is such an important part of the solution.
Co-chairs Jeff Lazarus and Jörn Schattenberg of the Innovations in NAFLD Care 2022 Series join the Surfers to review the initiative’s key elements and patient awareness goals.
Co-chairs of the Innovations in NAFLD Care 2022 initiative join the Surfers to review the initiative’s goals and agenda.
Jeff Lazarus and Jörn Schattenberg join the Surfers to discuss their new Innovations in NAFLD Care 2022 webinar and hybrid meeting series in a session whose dialogue blends medical, economic and public health discussions.
This episode uses quotes from Surfing the NASH Tsunami’s NASH-TAG 2022 coverage and comments from Roger Green to explore what we learned there about combination therapies.
Donna Cryer and Scott Friedman share perspectives on where all things NASH and NAFLD are heading in a conversation with Roger Green.
First-timers Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals) and Rachel Zayas (AGED Diagnostics) join the Surfers and guest KOL Ian Rowe to explore what NASH-TAG 2022 taught us about improving clinical trial efficiency by reducing screen fail rates.
First-timers Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals) and Rachel Zayas (AGED Diagnostics) join the Surfers and guest KOL Ian Rowe to explore messages for patients and regulators from the firecis NASH-TAG 2022.
First-timers Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals) and Rachel Zayas (AGED Diagnostics) join the Surfers and guest KOL Ian Rowe to discuss key takeaways from the fireside chats that closed NASH-TAG 2022.
First-timers Amy Articolo (Novo Nordisk), Erin Quirk (Terns Pharmaceuticals), and Rachel Zayas (AGED Diagnostics) join the Surfers and guest KOL Ian Rowe to identify the highest impact presentations and messages of NASH-TAG 2022.
NASH-TAG 2022 Wrap-Up: Finding New Disease Insights and Reconsidering Clinical Trial Design
The Surfers and “fifth Beatle” Jörn Schattenberg review the highs, lows and powerful moments of Day Two at NASH-TAG 2022.
Key Opinion Leaders Convene to Discuss Their Impressions from the First Day of NASH-TAG 2022.
NASH-TAG 2022 Asks: Are We Ready to Pivot on Testing Methods?
